Ohio is currently home to 3190 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Patient-Centered Outcomes in the Surgical Treatment of Uterovaginal Prolapse
Recruiting
The purpose of this study is to compare two types of surgery for the treatment of uterovaginal prolapse to determine which surgery works best from a patient's perspective and has the lowest number of short-term and long-term complications.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
04/23/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Uterine Prolapse
AlloSure Lung Assessment and Metagenomics Outcomes Study
Recruiting
ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of rejection (ACR, AMR) and allograft infection (Bacterial, Viral, Fungal, Mycobacterial, Parasitic).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Ohio State University, Columbus, Ohio
Conditions: Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Recruiting
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as p... Read More
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
04/23/2025
Locations: Indu and Raj Soin Medical Center, Beavercreek, Ohio
Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
The Re-Prosper HF Study
Recruiting
Heart failure with reduced ejection fraction (HFrEF) is a common cause for admission within the Veterans Affairs (VA) Health Care System. It is associated with severe impairment of physical and mental health status and carries a high risk of mortality. Even though significant progress has been made in understanding the disease process, currently, its management and treatment is limited. The investigators have discovered that a commonly used drug for the treatment of gout can be repurposed for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio
Conditions: Heart Failure
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
Recruiting
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: The Ohio State University /ID# 267590, Columbus, Ohio
Conditions: Open-angle Glaucoma, Ocular Hypertension
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
Recruiting
The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney, will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Kidney Cancer, Renal Cell Carcinoma
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Recruiting
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Cleveland Clinic Akron General, Akron, Ohio
Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Medtronic Terminate AF Study
Recruiting
The purpose of this study is to demonstrate the safety and effectiveness of the Cardioblate iRF and CryoFlex hand held devices for the treatment of non-paroxysmal AF.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: ProMedica Toledo, Toledo, Ohio
Conditions: Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
Stress Hydrocortisone In Pediatric Septic Shock
Recruiting
SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the incidence of new and progressive organ dysfunction (primary outcome) and proportion of children with poor outcomes, defined as death or severely imp... Read More
Gender:
ALL
Ages:
Between 1 month and 17 years
Trial Updated:
04/23/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Septic Shock
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
Recruiting
The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are: * Whether bitopertin increases pain-free sunlight exposure after 6 months of treatment in participants with EPP or XLP. * How PPIX concentration levels change from before bitopertin treatment to after 6 months of treatment. Researchers will compare bitopertin to a placebo look-alike substance that contains no drug. Partici... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/22/2025
Locations: Remington-Davis Clinical Research, Columbus, Ohio
Conditions: Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
Recruiting
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/22/2025
Locations: FALCON Research Site, Beachwood, Ohio
Conditions: Overweight or Obesity
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
Recruiting
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/22/2025
Locations: CTI Clinical Research Center, Cincinnati, Ohio
Conditions: Acute Migraine